Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

NNVC vs GNPX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NNVC Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 5–0 Matrix Metrics)

NNVC Overall Winner 6-Pillar Tally: NNVC 4 – 0 GNPX (2 Tie) Matrix Metrics: NNVC 5 – 0 GNPX

As of Nov 20, 2026, NanoViricides Inc. (NNVC) is the stronger overall head-to-head candidate over Genprex, Inc. (GNPX) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NNVC carries a Unified Composite Score of 48.1/100 (HOLD) at $1.14 (N/M Forward P/E, 0.0% operating margin), whereas GNPX carries 42.2/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: NNVC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.7); meanwhile GNPX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NNVC vs GNPX
NNVC NYSE American Head-to-Head Winner
NanoViricides Inc.
Pharmaceutical Preparations
$1.14
-2.56% 1D
Market Cap $29.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.95β · 69% Vol
Unified Composite Score
48.1 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 60.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 37.7 · SMA20: $1.32 · SMA50: $1.35
GNPX NASDAQ
Genprex, Inc. Common Stock
Pharmaceutical Preparations
$1.45
-13.17% 1D
Market Cap $2.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -4.68β · 96% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 25.0 Fund 47.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.2%), weak momentum, RSI 27
RSI-14: 26.6 · SMA20: $2.00 · SMA50: $2.48

6-Pillar Scorecard Institutional Category Breakdown (NNVC 4 – 0 GNPX)

Columns: Metric · NNVC · GNPX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale NNVC
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $29.9M $2.2M
3. Profitability & Quality NNVC
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -179.2% -233.7%
4. Balance Sheet & Cash Flow NNVC
Cash Generation (TTM) -$7.4M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $0.25 Book/Sh · -179.2% ROE $11.26 Book/Sh · -233.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NNVC
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NNVC (5) vs GNPX (0)
Institutional Metric NNVC GNPX Criterion Row Edge
Market Capitalization
Scale
$29.9M $2.2M Larger Scale NNVC
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-179.2% -233.7% Higher ROE NNVC
52-Week Range Position
Momentum
27% ($1–$2) 11% ($0–$10) Stronger Trend NNVC
Beta / 30D Volatility
Risk Regime
1.95β · 69% Vol -4.68β · 96% Vol Lower Realized Risk NNVC
Unified Institutional Score
Composite Signal
48.1 / 100 (HOLD) 42.2 / 100 (HOLD) Higher Composite NNVC
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.4M ($0.25 Book/Sh · -179.2% ROE) N/A ($11.26 Book/Sh · -233.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NNVC +8.78 pp
NNVC: -17.99% · GNPX: -26.77%
3M Horizon NNVC +53.69 pp
NNVC: -10.24% · GNPX: -63.93%
6M Horizon GNPX +107.08 pp
NNVC: -30.49% · GNPX: +76.59%
1Y Horizon NNVC +37.44 pp
NNVC: -19.15% · GNPX: -56.59%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NNVC vs GNPX. Trailing 12-month operating profitability (NNVC 0.0% vs GNPX 0.0%) and valuation multiples (NNVC N/M vs GNPX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

NNVC ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-179.2% · N/M
GNPX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-233.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NNVC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NNVC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GNPX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GNPX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NNVC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $29.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
GNPX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NNVC vs GNPX Key Questions & Quantitative Answers

As of Nov 20, 2026, NanoViricides Inc. (NNVC) is the stronger overall head-to-head candidate over Genprex, Inc. (GNPX) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NNVC carries a Unified Composite Score of 48.1/100 (HOLD) at $1.14 (N/M Forward P/E, 0.0% operating margin), whereas GNPX carries 42.2/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: NNVC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.7); meanwhile GNPX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NNVC leads the Growth & Scale pillar: NNVC posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with GNPX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, NNVC generates N/A in USD-normalized revenue versus N/A for GNPX. In operating R&D and SG&A reinvestment, NNVC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GNPX.

NNVC and GNPX trade at balanced relative valuation multiples. NNVC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas GNPX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NNVC (-179.2% ROE) versus GNPX (-233.7% ROE) capital efficiency.

In options market volatility and institutional positioning, NNVC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.95β · 69% Vol realized risk). By comparison, GNPX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-4.68β · 96% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.